摘要
严重急性呼吸综合征冠状病毒 2 (SARS-CoV-2) 是 COVID-19 传染病的病原体,通过呼吸道传播并已达到全球大流行的严重程度。随着疾病的恶化,COVID-19 的症状可能从轻微(发烧、干咳、呼吸急促)到严重的肺炎样呼吸道症状不等。与 SARS-CoV 不同,SARSCoV-2 对 ACE-2 受体具有更高的结合亲和力,这意味着其在人与人之间的传播率更高。尽管 ACE-2 在对各种器官表现出保护作用的肾素血管紧张素-醛固酮系统 (RAAS) 调节中具有重要意义,但它在 COVID-19 疾病的发病机制中发挥着重要作用。在感染 SARS-CoV-2 的患者中发现了对 ACE-2 肽酶活性的病毒干扰,导致促炎反应、高血压和多器官损伤。血管紧张素转换酶 2 受限于多种器官系统,但肺上皮细胞表面的 ACE-2 受体受到很大影响,这导致肺组织学的病理改变,可能进展为呼吸衰竭。病毒趋向性主要通过附着在宿主细胞中的血管紧张素转换酶-2受体上发生;因此,靶向 ACE-2 表达的药物可能会成为未来对抗 COVID-19 感染的治疗策略。重新利用药物的创新方法已显示出遏制日益严重的流行病的暂时有效性。本文主要关注在 COVID 感染期间表达的 ACE-2 受体的重要性以及现有药物疗法的再利用策略。
关键词: SARS-CoV-2、ACE-2 受体、严重急性呼吸综合征 (SARS)、抗病毒治疗、RAAS、COVID-19。
Current Molecular Medicine
Title:The Ineluctable Role of ACE-2 Receptors in SARS COV-2 Infection and Drug Repurposing as a Plausible SARS COV-2 Therapy: A Concise Treatise
Volume: 21 Issue: 10
关键词: SARS-CoV-2、ACE-2 受体、严重急性呼吸综合征 (SARS)、抗病毒治疗、RAAS、COVID-19。
摘要: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the etiological agent for the COVID-19 infectious disease that spreads via the respiratory route and has reached a drastic level of a global pandemic. Symptoms of COVID-19 may vary from mild (fever, dry cough, shortness of breath) to severe pneumonia-like respiratory symptoms as exacerbation of disease occurs. Unlike SARS-CoV, the SARSCoV- 2 has a higher binding affinity to ACE-2 receptors, which signifies its higher transmission rate from person to person. Even though ACE-2 is significant in the reninangiotensin- aldosterone system (RAAS) regulation that exhibits protection to various organs, it plays a significant role in COVID-19 disease pathogenesis. Viral interferences with the ACE-2 peptidase activity are found in SARS-CoV-2 infected patients leading to pro-inflammatory responses, hypertension and multi-organ damage. Angiotensinconverting enzyme-2 is constrained to a variety of organ systems, but surface ACE-2 receptors on lung epithelia are largely affected, which lead to pathological alterations in lung histology which may progress to respiratory failure. The viral tropism mainly occurs by the attachment to the angiotensin-converting enzymes-2 receptors in the host cell; thus drugs targeting ACE-2 expressions may arise as the future therapeutic strategy to combat COVID-19 infections. The innovative approach of repurposing drugs has shown temporary effectiveness to curb the rising pandemic. This article mainly focuses on the prominence of ACE-2 receptors which are expressed during the COVID infections and the repurposing strategy of available drug therapies.
Export Options
About this article
Cite this article as:
The Ineluctable Role of ACE-2 Receptors in SARS COV-2 Infection and Drug Repurposing as a Plausible SARS COV-2 Therapy: A Concise Treatise, Current Molecular Medicine 2021; 21 (10) . https://dx.doi.org/10.2174/1573405617666210204212024
DOI https://dx.doi.org/10.2174/1573405617666210204212024 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
C-reactive Protein, Infection, and Outcome After Acute Ischemic Stroke: A Registry and Systematic Review
Current Neurovascular Research Progress Towards Discovery of Antifibrotic Drugs Targeting Synthesis of Type I Collagen
Current Medicinal Chemistry Beyond Mitochondria, What Would be the Energy Source of the Cell?
Central Nervous System Agents in Medicinal Chemistry Curcumin Nanomicelle Improves Lipid Profile, Stress Oxidative Factors and Inflammatory Markers in Patients Undergoing Coronary Elective Angioplasty; A Randomized Clinical Trial
Endocrine, Metabolic & Immune Disorders - Drug Targets Peroxisome Proliferator-Activated Receptor (PPAR) Gamma Agonists as Therapeutic Agents for Cardiovascular Disorders: Focus on Atherosclerosis
Current Pharmaceutical Design Pathogenesis, Clinical Manifestation, Diagnosis, Pathological Findings, Treatment Options, Preventive Measures, and Risk Factors of COVID-19
Coronaviruses The Search for the Genetic Component of COPD: Role of the Clinical Phenotype
Current Respiratory Medicine Reviews TH2 Cytokines and Associated Transcription Factors as Therapeutic Targets in Asthma
Current Drug Targets - Inflammation & Allergy Editorial (Hot Topic: Metabolic Syndrome and Cardiovascular Health: A Look Beyond the Horizon)
Current Pharmaceutical Design Nailfold Capillaroscopy – Its Role in Diagnosis and Differential Diagnosis of Microvascular Damage in Systemic Sclerosis
Current Rheumatology Reviews New Biochemical Markers in Acute Coronary Syndromes
Current Medicinal Chemistry Atheromatosis Extent in Coronary Artery Disease is not Correlated with Apolipoprotein-E Polymorphism and its Plasma Levels, but Associated with Cognitive Decline
Current Alzheimer Research Simulating Physiology and Methods for Therapeutic Evaluation with Emphasis on Hypertension
Current Topics in Medicinal Chemistry Societal and Cultural Attitudes to Gout: An Important Consideration in the Successful Management of Gout among Maori in Aotearoa New Zealand
Current Rheumatology Reviews The Role of Matrix Metalloproteinases in Essential Hypertension
Current Topics in Medicinal Chemistry Effects of Drugs, Phytoestrogens, Nutrients and Probiotics on Endothelial Dysfunction in the Estrogen-Deficient State
Current Pharmaceutical Design Obstructive Sleep Apnea and Cardiovascular Disease - A New Target for Treatment
Current Pharmaceutical Design Editorial: Vascular Risk Estimation by Specialist Nurses
Current Vascular Pharmacology Epidemiological Aspects of Stroke in Very Old Patients
Cardiovascular & Hematological Disorders-Drug Targets Role of ARBs in the Blood Hypertension Therapy and Prevention of Cardiovascular Events
Current Drug Targets